MT Newswires
Arvinas' Trial of ARV-102 to Treat Parkinson Shows Sharp Reduction in LRRK2
➖
AI Sentiment
Neutral
5/10
- Home
- ARVN
ARVN
Arvinas Inc.
as of 03-23-2026 3:53pm EST
$10.47
$0.44
-4.03%
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 781.0M | IPO Year: | 2018 |
| Target Price: | $15.35 | AVG Volume (30 days): | 763.2K |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | 58.84 |
| 52 Week Low/High: | $5.90 - $14.22 | Next Earning Date: | 04-30-2026 |
| Revenue: | $262,600,000 | Revenue Growth: | -0.30% |
| Revenue Growth (this year): | -65.26% | Revenue Growth (next year): | -17.25% |
| P/E Ratio: | -9.57 | Index: | N/A |
| Free Cash Flow: | -275700000.0 | FCF Growth: | N/A |
AI-Powered ARVN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 70.15%
70.15%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Arvinas Inc. (ARVN)
Berkowitz Noah
Sell
Chief Medical Officer
ARVN Mar 18, 2026
Avg Cost/Share
$11.10
Shares
6,435
Total Value
$71,431.07
Owned After
202,503
SEC Form 4
Morrison Briggs
Buy
Director
ARVN Mar 6, 2026
Avg Cost/Share
$13.40
Shares
20,000
Total Value
$268,070.00
Owned After
96,021
SEC Form 4
Houston John G
Sell
Director
ARVN Feb 27, 2026
Avg Cost/Share
$13.21
Shares
35,297
Total Value
$466,153.58
Owned After
1,152,792
Teel Randy
Sell
President and CEO
ARVN Feb 23, 2026
Avg Cost/Share
$12.16
Shares
4,786
Total Value
$58,197.76
Owned After
149,696
Loomis David K
Sell
Chief Accounting Officer
ARVN Feb 23, 2026
Avg Cost/Share
$12.16
Shares
1,108
Total Value
$13,473.28
Owned After
29,692
SEC Form 4
Cacace Angela M
Sell
Chief Scientific Officer
ARVN Feb 23, 2026
Avg Cost/Share
$12.16
Shares
3,609
Total Value
$43,885.44
Owned After
147,623
Berkowitz Noah
Sell
Chief Medical Officer
ARVN Feb 13, 2026
Avg Cost/Share
$11.89
Shares
5,685
Total Value
$67,594.65
Owned After
202,503
SEC Form 4
Teel Randy
Sell
President and CEO
ARVN Feb 13, 2026
Avg Cost/Share
$11.89
Shares
4,403
Total Value
$52,351.67
Owned After
149,696
SEC Form 4
Loomis David K
Sell
Chief Accounting Officer
ARVN Feb 13, 2026
Avg Cost/Share
$11.89
Shares
1,016
Total Value
$12,080.24
Owned After
29,692
SEC Form 4
Cacace Angela M
Sell
Chief Scientific Officer
ARVN Feb 13, 2026
Avg Cost/Share
$11.89
Shares
4,592
Total Value
$54,598.88
Owned After
147,623
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Berkowitz Noah | ARVN | Chief Medical Officer | Mar 18, 2026 | Sell | $11.10 | 6,435 | $71,431.07 | 202,503 | |
| Morrison Briggs | ARVN | Director | Mar 6, 2026 | Buy | $13.40 | 20,000 | $268,070.00 | 96,021 | |
| Houston John G | ARVN | Director | Feb 27, 2026 | Sell | $13.21 | 35,297 | $466,153.58 | 1,152,792 | |
| Teel Randy | ARVN | President and CEO | Feb 23, 2026 | Sell | $12.16 | 4,786 | $58,197.76 | 149,696 | |
| Loomis David K | ARVN | Chief Accounting Officer | Feb 23, 2026 | Sell | $12.16 | 1,108 | $13,473.28 | 29,692 | |
| Cacace Angela M | ARVN | Chief Scientific Officer | Feb 23, 2026 | Sell | $12.16 | 3,609 | $43,885.44 | 147,623 | |
| Berkowitz Noah | ARVN | Chief Medical Officer | Feb 13, 2026 | Sell | $11.89 | 5,685 | $67,594.65 | 202,503 | |
| Teel Randy | ARVN | President and CEO | Feb 13, 2026 | Sell | $11.89 | 4,403 | $52,351.67 | 149,696 | |
| Loomis David K | ARVN | Chief Accounting Officer | Feb 13, 2026 | Sell | $11.89 | 1,016 | $12,080.24 | 29,692 | |
| Cacace Angela M | ARVN | Chief Scientific Officer | Feb 13, 2026 | Sell | $11.89 | 4,592 | $54,598.88 | 147,623 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 24, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 24, 2026 · 100% conf.
AI Prediction BUY
1D
-0.21%
$12.34
Act: +7.48%
5D
+6.24%
$13.14
Act: +8.00%
20D
-1.25%
$12.22
Price: $12.37 Prob +5D: 100% AUC: 1.000
0001628280-26-010865
arvn-202602240001655759FALSE00016557592026-02-242026-02-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026
Arvinas, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3867247-2566120 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
5 Science Park 395 Winchester Ave. New Haven, Connecticut 06511 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (203) 535-1456 Not applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per shareARVNThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On February 24, 2026, Arvinas, Inc. announced its financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
99.1 Press Release issued by the Registrant on February 24, 2026.
104Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARVINAS, INC.
Date: February 24, 2026 By:/s/ Andrew Saik Andrew Saik Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0001628280-25-049235
arvn-202511050001655759FALSE00016557592025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025
Arvinas, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3867247-2566120 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
5 Science Park 395 Winchester Ave. New Haven, Connecticut 06511 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (203) 535-1456 Not applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per shareARVNThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On November 5, 2025, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2025 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.Description
99.1 Press Release issued by the Registrant on November 5, 2025.
104Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARVINAS, INC.
Date: November 5, 2025 By:/s/ Andrew Saik Andrew Saik Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 6, 2025
0001655759-25-000136
arvn-202508060001655759FALSE00016557592025-08-062025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025
Arvinas, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3867247-2566120 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
5 Science Park 395 Winchester Ave. New Haven, Connecticut 06511 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (203) 535-1456 Not applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per shareARVNThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On August 6, 2025, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2025 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.Description
99.1 Press Release issued by the Registrant on August 6, 2025.
104Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARVINAS, INC.
Date: August 6, 2025 By:/s/ Andrew Saik Andrew Saik Chief Financial Officer
Latest Arvinas Inc. News
ARVN Breaking Stock News: Dive into ARVN Ticker-Specific Updates for Smart Investing
Compare ARVN vs Leading Stocks
See how ARVN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ARVN Arvinas Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.